One form has been associated with DXYS154.Secondary chronic intestinal pseudo-obstruction can occur as a consequence of a number of other conditions including:

Hirschsprungs disease - the absence of colonic nerve cells
Chagas disease - a chronic parasitic infection of the colon leading to loss of nerve endings
Kawasaki disease - a rare presentation for this particular autoimmune disorder of the vasculature
Parkinsons disease - related to the neurodegeneration of gastrointestinal tract
Autoimmune conditions - conditions including systemic lupus erythematosus and scleroderma lead to collagen vascular deposition and gastrointestinal motility disruption
Mitochondrial disease - IPO is a known presentation for mitochondrial disease
Endocrine disorders
Certain medications.The term may be used synonymously with enteric neuropathy if a neurological cause is suspected. Diagnosis
The symptoms of IPO are nonspecific. It is not unusual for patients to present repeatedly and to undergo numerous tests. Mechanical causes of intestinal obstruction must be excluded to reach a diagnosis of pseudo-obstruction. Attempts must also be made to determine whether the IPO is the result of a primary or secondary condition. A diagnostic work-up may include:
Gastric motility studies
Imaging studies:
 X-rays - may show intestinal air fluid levels (seen with true mechanical intestinal obstruction)
CT scans
Barium enema
Blood tests
Upper and lower endoscopies
Manometry - used to measure pressure of esophagus and stomach

Treatment
Treatment for IPO (acute or chronic) is aimed at removing the disease process and/or managing the complications present. Focus is placed on management of pain, gastrointestinal symptoms, nutritional deficiencies, fluid status, infection control, and improving quality of life. When CIPO is secondary to another disease, treatment is addressed towards the underlying condition.
It is a rare type of skin cancer, with a 2013 incidence of only 0.7 per 100,000 persons in the U.S. As of 2005, roughly 2,500 new cases of MCC are diagnosed each year in the United States, as compared to around 60,000 new cases of malignant melanoma and over 1 million new cases of nonmelanoma skin cancer. Similar to melanoma, the incidence of MCC in the US is increasing rapidly. Worldwide, MCC is most commonly found in regions with increased sun exposure. Australia is the country with the highest incidence of MCC but has a lower incidence of MCV-positive MCC than observed in other countries.Since 2006, it has been known that other primary cancers increase the risk of MCC significantly, especially in those with the prior multiple myeloma, chronic lymphocytic leukemia, and malignant melanoma. Immunosuppression including HIV infection or immunosuppressant therapy following organ transplant or for autoimmune disease can also increase the odds of developing MCC. History
Friedrich Sigmund Merkel (1845–1919) was a German anatomist and histopathologist who first described the Tastzellen (touch cells) in the skin in 1875. In 1878 the term Merkel cell was coined by the anatomist Robert Bonnet (1851–1921). Merkel-cell carcinoma was first described in 1972 by Cyril Toker. He reported five cases of trabecular carcinoma of the skin.